Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) EBITDA Margin (2017 - 2025)

Assembly Biosciences has reported EBITDA Margin over the past 8 years, most recently at 52.13% for Q4 2025.

  • Quarterly results put EBITDA Margin at 52.13% for Q4 2025, up 19336.0% from a year ago — trailing twelve months through Dec 2025 was 8.23% (up 13310.0% YoY), and the annual figure for FY2025 was 8.23%, up 13310.0%.
  • EBITDA Margin for Q4 2025 was 52.13% at Assembly Biosciences, up from 83.48% in the prior quarter.
  • Over the last five years, EBITDA Margin for ASMB hit a ceiling of 52.13% in Q4 2025 and a floor of 300.9% in Q3 2021.
  • Median EBITDA Margin over the past 4 years was 134.88% (2024), compared with a mean of 125.35%.
  • Biggest five-year swings in EBITDA Margin: crashed -29046bps in 2021 and later surged 19336bps in 2025.
  • Assembly Biosciences' EBITDA Margin stood at 300.9% in 2021, then surged by 50bps to 150.33% in 2023, then increased by 6bps to 141.23% in 2024, then surged by 137bps to 52.13% in 2025.
  • The last three reported values for EBITDA Margin were 52.13% (Q4 2025), 83.48% (Q3 2025), and 106.21% (Q2 2025) per Business Quant data.